XML 68 R54.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Significant Agreements - Additional Information (Details) $ in Millions |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Jul. 31, 2020 USD ($) | Oct. 31, 2023 USD ($) | Aug. 31, 2023 USD ($) | Apr. 30, 2023 GBP (£) | Aug. 31, 2022 USD ($) | Jul. 31, 2022 | Jan. 31, 2022 GBP (£) | Jun. 30, 2020 USD ($) | Sep. 30, 2018 USD ($) | Dec. 31, 2023 GBP (£) | Dec. 31, 2023 USD ($)
License Agreement | Cancer Research Technology and the University of Manchester |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payment of one-time option exercise fee | £ |  |  |  |  |  |  | £ 250,000 |  |  |  |
Payments for achievement of specific development and regulatory approval events | £ |  |  |  |  |  |  | £ 19,500,000 |  |  |  |
Milestone payments relating to first and second tumor histologies | £ |  |  |  | £ 750,000 |  |  |  |  |  |  |
License Agreement | Amgen Clinical Trial Collaboration and Supply Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Pay for external third-party cost percentage |  |  |  |  |  | 50.00% |  |  |  |  |
Maximum | License Agreement | Novartis International Pharmaceuticals Limited |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Contingent development and sales-based milestone payments |  |  |  |  |  |  |  |  | $ 29.0 |  |
Maximum | License Agreement | Cancer Research Technology and the University of Manchester |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Additional payments for achievement of specific development and regulatory approval events | £ |  |  |  |  |  |  |  |  |  | £ 18,750,000 |
Milestone payments of phase two relating to first and second tumor histologies | £ |  |  |  |  |  |  |  |  |  | 1,500,000 |
Milestone payments of phase three relating to first and second tumor histologies | £ |  |  |  |  |  |  |  |  |  | £ 2,250,000 |
GSK Collaboration Agreement | GSK |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Development and regulatory milestone payment eligible to receive |  |  |  |  |  |  |  |  |  |  | $ 13.0
GSK Collaboration Agreement | GSK | License Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 100.0 |  |  |  |  |  |  |  |  |  |
Number of days of notice period for terminating agreement |  |  |  |  |  |  |  | 90 days |  |  |
Pol Theta Program |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payment received for achievement of initial preclinical development milestone |  |  | $ 3.0 |  | $ 3.0 |  |  |  |  |  |
Milestone payment received clinical evaluation |  |  | $ 7.0 |  |  |  |  |  |  |  |
Additional payment of development milestone to achieve |  |  |  |  |  |  |  |  |  |  | 10.0
Pol Theta Program | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Development and regulatory milestone payment eligible to receive |  |  |  |  |  |  |  | $ 485.0 |  |  |
Commercial milestone payment eligible to receive |  |  |  |  |  |  |  | $ 475.0 |  |  |
Development milestone payment eligible to receive |  |  |  |  |  |  |  |  |  |  | $ 465.0
WRN Program |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Development costs sharing percentage |  |  |  |  |  |  |  | 20.00% |  |  |
Milestone payment received for achievement of initial preclinical development milestone |  | $ 3.0 |  |  |  |  |  |  |  |  |
Milestone payment received clinical evaluation |  | $ 3.0 |  |  |  |  |  |  |  |  |
Percentage of profit share |  |  |  |  |  |  |  | 50.00% |  |  |
WRN Program | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Commercial milestone payment eligible to receive |  |  |  |  |  |  |  | $ 475.0 |  |  |
Development milestone payment eligible to receive |  |  |  |  |  |  |  | $ 485.0 |  |  |
WRN Program | GSK |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Development costs sharing percentage |  |  |  |  |  |  |  | 80.00% |  |  |

X
- Definition Additional payment of development milestone to achieve. + References No definition available. + Details
Name: | idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional payments for achievement of specific development and regulatory approval events. + References No definition available. + Details
Name: | idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commercial milestone payment to be received. + References No definition available. + Details
Name: | idya_CommercialMilestonePaymentToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contingent development and sales based milestone payments. + References No definition available. + Details
Name: | idya_ContingentDevelopmentAndSalesBasedMilestonePayments
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development and regulatory milestone payment to be received. + References No definition available. + Details
Name: | idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development costs sharing percentage. + References No definition available. + Details
Name: | idya_DevelopmentCostsSharingPercentage
Namespace Prefix: | idya_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development milestone payment to be received. + References No definition available. + Details
Name: | idya_DevelopmentMilestonePaymentToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payment received clinical evaluation + References No definition available. + Details
Name: | idya_MilestonePaymentReceivedClinicalEvaluation
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payment received for achievement of initial preclinical development milestone. + References No definition available. + Details
Name: | idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments of phase three relating to first and second tumor histologies. + References No definition available. + Details
Name: | idya_MilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments of phase two relating to first and second tumor histologies. + References No definition available. + Details
Name: | idya_MilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments relating to first and second tumor histologies. + References No definition available. + Details
Name: | idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of days of notice period for terminating collaboration agreement. + References No definition available. + Details
Name: | idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement
Namespace Prefix: | idya_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pay for external third-party cost percentage. + References No definition available. + Details
Name: | idya_PayForExternalThirdPartyCostPercentage
Namespace Prefix: | idya_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of one-time option exercise fee. + References No definition available. + Details
Name: | idya_PaymentOfOneTimeOptionExerciseFee
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments for achievement of specific development and regulatory approval events. + References No definition available. + Details
Name: | idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of profit share. + References No definition available. + Details
Name: | idya_PercentageOfProfitShare
Namespace Prefix: | idya_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | idya_UpfrontPayment
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=idya_NovartisInternationalPharmaceuticalsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |